Literature DB >> 21601348

Eukaryotic initiation factor 6 (eif6) overexpression affects eye development in Xenopus laevis.

N De Marco1, M Tussellino, A Vitale, C Campanella.   

Abstract

The translation initiation factor eif6 has been implicated as a regulator of ribosome assembly, selective mRNA translation and apoptosis. Many of these activities depend upon the phosphorylation of eif6 serine 235 by PKC. Previous data showed that eif6 binds to the 60S ribosomal subunit when unphosphorylated, inhibiting assembly with the 40S subunit. Phosphorylation of Ser235 releases eif6 from the 60S subunit and allows assembly. eif6 acts as an anti-apoptotic factor via regulation of the bcl2/bax balance and acts selectively upstream of bcl2. This activity also depends upon phosphorylation of eif6 Ser235. One of the consequences of eif6 overexpression in Xenopus embryos is aberrant eye development. Here we evaluate the eye phenotype and show that it is transient. We show that the whole eye, particularly the retina layers, of the embryos injected with eif6-encoding mRNA recover by stage 42. Embryos over-expressing eif6 have normal expression of anterior- and brain-specific markers, indicating that outside the eye field, other neural regions appear unaffected by the eif6 injection. No eye defect was detected when morpholinos were used to reduce eif6 protein synthesis. We tested how two known pathways of eif6 function with respect to alteration of eye development. We found that injection of bcl2 did not produce the eye phenotype and eif6-bax co-injection did not rescue the eye defect, suggesting that the eye phenotype is not bearing on the anti-apoptotic role played by eif6 is not linked to its role as an anti-apoptotic factor. We also determined that PKC-dependant phosphorylation of Ser235 in eif6 is not required to produce defective eye development. These results indicate that the aberrant eye phenotype, produced by eif6 overexpression, is not directly linked to the PKC-regulated effects of eif6 on translation and ribosomal subunit interaction or on eif6 anti-apoptotic properties. 2011 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21601348     DOI: 10.1016/j.diff.2011.05.002

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  4 in total

1.  Diagnostic and prognostic utility of eIF6 in glioblastoma: a study based on TCGA and CGGA databases.

Authors:  Jian Liang; Fengyu Liu; Yaoqiang Yang; Xing Li; Guangmou Cai; Jianxuan Cao; Bo Zhang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.

Authors:  Liping Sun; Shuguang Liu; Xiaopai Wang; Xuefeng Zheng; Ya Chen; Hong Shen
Journal:  J Transl Med       Date:  2021-05-20       Impact factor: 5.531

3.  The role of eukaryotic translation initiation factor 6 in tumors.

Authors:  Wei Zhu; Gui Xian Li; Hong Lang Chen; Xing Yan Liu
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

4.  Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway.

Authors:  Zechen Zhao; Weiming Chu; Yang Zheng; Chao Wang; Yuemei Yang; Teng Xu; Xueming Yang; Wei Zhang; Xu Ding; Gang Li; Hongchuang Zhang; Junbo Zhou; Jinhai Ye; Heming Wu; Xiaomeng Song; Yunong Wu
Journal:  Cell Commun Signal       Date:  2021-12-18       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.